Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment. Collaboration between research, led by Dr. Jordi Bruna’s team at IDIBELL, and industry, led to the identification and successful testing of a new molecule capable of preventing this neurological complication. This molecule could potentially become the first existing treatment to prevent this frequent adverse effect and improve the quality of life of cancer patients.
